




RealRate

PHARMACEUTICAL 2015

Tetraphase Pharmaceuticals INC
Rank 91 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Tetraphase Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tetraphase Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 102% points. The greatest weakness of Tetraphase Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 329%, being 75% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	126,597
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,276
Liabilities, Non-Current	0
Other Assets	307
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-976
Other Revenues	9,098
Property and Equipment	300
Research and Development	61,932
Selling, General and Administrative Expense	12,932

Output Variable	Value in 1000 USD
Assets	127,204
Liabilities	17,276
Expenses	74,864
Revenues	9,098
Stockholders Equity	109,928
Net Income	-66,742
Comprehensive Net Income	-66,742
BaseVar	114,709
ECR before LimitedLiability	239%
Economic Capital Ratio	329%